J. Milton Harris, Ph.D.
Founder, Chairman of the Board

Dr. Harris received his B.S. degree in Chemistry from Auburn University in 1963, his Ph.D. in Organic Chemistry from the University of Texas in Austin in 1969, and he was an NIH postdoctoral fellow at Princeton University from 1969 through 1970. He was Distinguished Professor of Chemistry at the University of Alabama before founding Shearwater Polymers, Inc. in 1992 to advance polyethylene glycol "PEG" technology. Shearwater successfully created, manufactured and partnered poly(ethylene glycol) technology for over 20 product candidates, from which multiple pharmaceutical and biotechnology products are now marketed with annual sales of over $5 billion. Shearwater was sold to Inhale Therapeutic Systems (now Nektar Therapeutics, Inc.) in 2001. Dr. Harris has over 200 publications and patents and has authored two key textbooks: Poly(ethylene glycol) Chemistry, Biotechnical and Biomedical Applications, Plenum Press, 1992; and Poly(ethylene glycol) Chemistry and Biological Applications, American Chemical Society, 1997. Dr. Harris is the recipient of the Nagai Innovation Award (2005, Controlled Release Society) and is a member of the Swedish Academy of Engineering Sciences.

Randall Moreadith, MD, Ph.D.
President and Chief Executive Officer

Randall Moreadith joined Serina Therapeutics in September 2010 as Chief Executive Officer. Prior to joining Serina, Dr. Moreadith, 56, was Chief Development Officer at Nektar Therapeutics where he built a clinical and drug development program that successfully moved several of the company's PEGylated small molecule drugs into the clinic, including the launch of NKTR-102 into four clinical indications (ovarian, breast, cervical and colorectal cancer). He was formerly the Executive Vice President and Chief Medical Officer of Cardium Therapeutics where he led the advancement of novel DNA-based therapeutics into Phase 2b and Phase 3 late-stage development. Before Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. where he led the Clinical, Regulatory and Quality Assurance Groups. Prior to that, Dr. Moreadith was co-Founder, President and Chief Operating Officer of ThromboGenics Ltd., a leader in the field of thrombosis drug development. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development. Dr. Moreadith began his career in the pharmaceutical industry as Principal Medical Officer of Quintiles, Inc., the world's leading pharmaceutical services organization, where he led the Cardiovascular Therapeutics Group.

Dr. Moreadith has published more than 50 scientific papers and multiple book chapters, is an inventor on four patents and has received numerous awards for his achievements. He received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. He received his Ph.D. from Johns Hopkins University, and following his Fellowship in Cardiology at Duke University he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith was a member of the faculty of the University of Texas Southwestern Medical Center, where he was an Established Investigator of the American Heart Association.

Michael Bentley, PhD
Founder, Chief Scientific Officer

Dr. Bentley received his B.S. (1963) and M.S. (1965) degrees in Chemistry from Auburn University, his Ph.D. in Organic Chemistry from the University of Texas in Austin in 1968, and did postdoctoral work at the University of California, Berkeley in 1968-9. Dr. Bentley was Professor and Chair of Chemistry at the University of Maine and won the Presidential Research and Creative Achievement Award at the University. He joined Shearwater Corporation in 1997 to head its research group and begin a drug development program there. Prior to this time Shearwater had focused on supply of PEG reagents to pharmaceutical companies. Dr. Bentley utilized Shearwater's polyethylene glycol chemistry to create several new platforms for the enhancement and enablement of PEG-small molecule pharmaceutical conjugates for sustained drug delivery and for membrane barrier exclusion. This technology now forms the basis of multiple products in human clinical trials at Nektar, including for the treatment of cancer and opioid-induced constipation. The latter product was recently licensed to AstraZeneca in a billion-dollar deal. Dr. Bentley has numerous patents and publications in several areas of chemistry. Dr. Bentley has been a Fulbright Senior Research Scholar and a Fellow of the Japan Agency for Science and Technology.

Lonnie S. McMillian
is co-founder of ADTRAN, a leading global provider of networking and communications equipment based in Huntsville, Alabama. Mr. McMillian served on the ADTRAN board of directors from 1986 through his retirement in December 2002. He was director emeritus of the board from 2002 until 2006. Mr. McMillian also guided ADTRAN in a variety of executive management roles including vice president of engineering and senior vice president. Prior to ADTRAN, Mr. McMillian was vice president of engineering for Universal Data Systems. He held similar positions with Motorola after the company purchased Universal Data Systems in 1979. Mr. McMillian's career also includes several other management positions, including chief engineer for SCI Systems, Inc., an aerospace-focused, electronics manufacturing firm. He also helped establish and direct Systems Engineering Laboratories, Inc., a Florida-based scientific computer manufacturing company.

Currently, Mr. McMillian is president of the Alpha Foundation, an Alabama-based, nonprofit organization committed to improving the human condition through grants to educational, scientific and other charitable groups. He is also co-chairman of the board of directors of the HudsonAlpha Institute for Biotechnology.

James R. Hudson, Jr.
In 1987, Mr. Hudson founded Research Genetics in Huntsville, Alabama. He served as chief executive until 2000 when the company was acquired by Invitrogen (now Life Technologies, Inc.) in a deal valued at $138 million. Prior to the merger, Research Genetics had become the world's leader in genetic linkage products and an integral partner in the Human Genome Project coordinated by the U.S. Department of Energy and the National Institutes of Health. Mr. Hudson has advised and incubated multiple companies in industries ranging from internet services to genetics research.

Currently, Mr. Hudson serves as co-chairman of the board of directors of the HudsonAlpha Institute for Biotechnology, a nonprofit research institute founded in Huntsville with a mission to use biotechnology to improve human health, stimulate economic development and inspire Alabama's youth to seek careers in science. He also serves as vice president of CityScapes LLC, a company focused on downtown revitalization projects, particularly those appealing to young professionals.